Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo cough/cold sales grow 27% in 2nd quarter, contributing to 11% OTC sales gain.

This article was originally published in The Tan Sheet

Executive Summary

PERRIGO COUGH/COLD SALES RISE 27% IN THE SECOND QUARTER ended Dec. 31 because of a "much stronger" cough and cold season than last year, the company said Feb. 6. In the first half of fiscal 1996, cough/cold product sales were ahead 20%. In contrast, however, a "moderate" flu season as well as a "soft and competitive" market caused analgesic sales to drop "slightly" in the quarter, the Allegan, Mich.-based store-brand manufacturer noted
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084774

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel